Stock MDG1 MEDIGENE AG
Add to a list
To use this feature you must be a member
Log inSign up

News Medigene AG

Equities

MDG1

DE000A1X3W00

Market Closed - Xetra
Other stock markets
 11:36:24 2024-04-26 am EDT 		After market 01:34:35 pm
1.505 EUR -5.64% Intraday chart for Medigene AG 1.518 +0.86%
Apr. 25 Medigene AG Presents Streamlined 6-Day, High Stemness Tcr-T Therapy Production Process CI
Apr. 08 Medigene AG Presents Favorable Safety Profile of TCR-T Cells with Costimulatory Switch Protein at AACR Annual Meeting 2024 CI

Summary

Search
See the results
Unlock all the news on all businesses: Never miss an investment opportunity again!
100% Free Registration
Medigene : Quartely Statement 2024
PU
Medigene AG reports Financial Results and Business Update for Q1 2024
GL
Medigene presents streamlined 6-day, high stemness TCR-T therapy production process
GL
Medigene AG Presents Streamlined 6-Day, High Stemness Tcr-T Therapy Production Process
CI
Medigene to Present at Upcoming Scientific Conferences
GL
Medigene Presents Favorable Safety Profile of TCR-T Cells with Costimulatory Switch Protein at AACR Annual Meeting 2024
GL
Medigene AG Presents Favorable Safety Profile of TCR-T Cells with Costimulatory Switch Protein at AACR Annual Meeting 2024
CI
Medigene Gets European Patent for T-Cell Receptor Technology
MT
Medigene AG Secures European Patent for its iM-TCR Technology
GL
Medigene AG Secures European Patent for Its iM-TCR Technology
CI
Medigene AG Reports Earnings Results for the Full Year Ended December 31, 2023
CI
Transcript : Medigene AG, 2023 Earnings Call, Mar 28, 2024
Medigene : Statement on Corporate Governance 2023
PU
Medigene AG Reports Full-Year 2023 Financial Results and Provides Corporate Update
GL
Medigene Ag Provides Earnings Guidance for 2024
CI
Medigene : Declaration of Conformity 2024
PU
Medigene AG to participate in the H.C. Wainwright 2nd Annual Cell Therapy Virtual Conference
GL
Medigene AG to report full year 2023 financial results on March 28, 2024
GL
Medigene to Present Favorable Safety Profile of TCR-T Cells upon Addition of Costimulatory Switch Protein with a Poster Presentation at AACR 2024 Annual Meeting
GL
Medigene AG Expands Patent Portfolio in Japan for iM-TCR Technology to Directly Control TCR-T Safety and Efficacy, In Vivo
GL
No results for this search
All News Analyst Reco. Highlights Insiders Transcripts Press Releases Official Publications Other languages Trading Ideas MarketScreener Editorial Features MarketScreener Strategies

Filters

Search

Announcement Date

Since

Until

  1. Stock Market
  2. Equities
  3. MDG1 Stock
  4. News Medigene AG